Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer

Urologia Internationalis

Volumn 60, Issue SUPPL. 1, 1998, Pages 9-17

  Tunn, U W ^a   Bargelloni, U ^b   Cosciani, S ^c   Fiaccavento, G ^d   Guazzieri, S ^e   Pagano, F ^f  

^a Academic Hospital   (Germany)

^b Cittadella General Hospital   (Italy)

^c Civil Hospital of Brescia   (Italy)

^d Hospital of Portogruaro   (Italy)

^e Regional Hospital of Belluno   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

3 month depot; Advanced metastatic prostate cancer; Leuprorelin; LH RH analogue; Pharmacokinetics; Prostate cancer

Indexed keywords

ANDROSTANOLONE; ANTIANDROGEN; GONADORELIN DERIVATIVE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; GERMANY; HORMONE BLOOD LEVEL; HOT FLUSH; HUMAN; HYPOPHYSIS; ITALY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; TESTOSTERONE BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DIHYDROTESTOSTERONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUPROLIDE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 0031952255     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056540     Document Type: Conference Paper

References (13)

1. Debruyne FMJ, Dijkman GA: Advances and trends in hormonal therapy for advanced prostate cancer. Eur Urol 1995;28:177-188.
2. Kienle E, Lübben G: The German Leuprorelin Study Group: Efficacy and safety of leuprorelin acetate depot for prostate cancer. Urol Int 1996;56(suppl 1):23-30.
3. Ogawa Y, Okada H, Heya T, Shimamoto T: Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: Serum drug level profiles and pharmacological effects in animals. J Pharm Pharmacol 1989;41:439-444.
4. Okada H, Yamamoto M, Toshiro H, Inoue Y: Drug delivery using biodegradable microspheres. J Controlled Release 1994;28:121-129.
5. Okada H, Doken Y, Ogawa Y, Toguchi H: Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers. Pharm Res 1994;118:1143-1147.
6. Okada H, Doken Y, Ogawa Y, Toguchi H: Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs. Pharm Res 1994;118:1199-1203.
7. Fornara P, Jocham D: Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma. Urol Int 1996;56(suppl 1): 18-22.
8. Yamazaki I, Okada H: A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin. Endocrinol Jpn 1980;27:593-605.
9. Janknegt RA: Buserelin 2-month implant in advanced prostate cancer - 3-year interim evaluation of a phase III study (abstract 121). Gynecol Endocrinol 1996;10(suppl 1).
10. Bouchot O, Lahlou N, Roger M, Blumberg J, Dufour-Esquerré F, Ispas S: Phase II study of decapeptyl sustained release form (3 months) in patients with prostate cancer (abstract 125). Gynecol Endocrinol 1996;10(suppl 1).
11. Debruyne FMJ: Zoladex 10.8 mg depot for prostate cancer (abstract 120). Gynecol Endocrinol 1996;10(suppl 1).
12. Mazzei T, Mini E, Rizzio M, Periti P: Human pharmacokinetic and pharmaco-dynamic profiles of leuprorelin acetate depot in prostatic cancer patients. J Int Med Res 1990;18(suppl 1):42-56.
13. Wechsel HW, Zerbib M, Pagano F, Coptcoat MJ: Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate IM- and 3-M-depot in patients with advanced prostatic cancer. Eur Urol 1996;30(suppl 1):7-14.